💡 在您使用本产品前请认真阅读说明书,这对您顺利完成实验很有帮助。
|
🏷️ 产品编码
RB9T37014663
|
🧬 中文名称
Andecaliximab ELISA试剂盒(靶标:)
|
|
📝 英文名称
Andecaliximab ELISA Kit
| |
|
🔬 应用
ELISA
| |
|
🔢 登录号
P14780
|
🔹 检测方法
Colorimetric
|
|
🔹 灵敏度
0.156 μg/ml
|
🔹 检测范围
0.31-5 μg/mL
|
|
🔹 回收率
80-120%
|
🔹 样本类型
Plasma, Serum
|
|
🔹 检测类型
Quantitative
|
🔹 背景信息
Andecaliximab (formerly GS-5745; Gilead Sciences, Inc.), a recombinant chimeric IgG4 monoclonal antibody (mAb), was engineered to remove T-cell epitopes to reduce immunogenicity risk. Andecaliximab selectively binds and inhibits matrix metalloproteinase-9 (MMP9) with minimal cross-reactivity to other matrix metalloproteinases, including the highly homologous matrix metalloproteinase-2 (MMP-2). Andecaliximab is under development for the treatment of cystic fibrosis, gastric cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), rheumatoid arthritis (RA), Crohn's disease (CD), and ulcerative colitis (UC). In a recent phase 1 dose-escalation study in patients with UC, andecaliximab had good tolerability and was associated with a numerically greater percentage of clinical, endoscopic, and histological responses in patients relative to placebo over a 5-week treatment period. A phase 2/3 trial, evaluating the safety and efficacy of andecaliximab to induce and maintain clinical remission in patients with moderate to severe UC, was initiated. A planned interim futility analysis following an 8-week induction period in the first 150 patients resulted in the termination of the study due to lack of efficacy.
|
|
🏷️ 别名
GS-5745, 1518996-49-0
| |
❄️ 稳定性和储存
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
🚚 运输条件
2-8 ℃
⚠️ For Research Use Only.